IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck

IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck

''结论'': Among the screened immune/inflammation nodes, IL-11 currently ranks highest because it crosses the strongest available threshold: direct mouse healthspan + lifespan benefit, not merely local inflammation readouts.

''Key evidence'':
# PMID 39020175 / Nature 2024: anti-IL-11 from 75 weeks of age until death extended median lifespan by 22.5% in male mice and 25% in female mice.
# The same study reports broad healthspan benefit and reduced age-related pathology, so IL-11 is materially stronger than candidates supported only by tissue or immune readouts.

''Sorting rule'':
# If an immune/inflammation candidate has direct lifespan data plus multi-organ pathology improvement, it should be ranked above nodes supported only by mechanistic or tissue-local evidence.
# Even so, IL-11 still requires caution before upgrading to a universal human longevity bottleneck: mouse lifespan efficacy is necessary but not sufficient.